Consultation on the Prescription Drug List: Hydroquinone
The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to add hydroquinone to the Prescription Drug List (PDL) when sold in a concentration greater than 2% in topical products. Only the Human part of the PDL is proposed to be revised.
A question-and-answer document has also been created to explain some of the changes to the new Prescription Drug List and the administrative process for assigning prescription status.
How to Get Involved
This consultation is open for comment until April 17, 2017. Please read through the information provided in the link below titled Consultation Document. Once read, please submit your comments via email, facsimile or by mail to:
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Interested parties are encouraged to provide comments and suggestions by April 17, 2017.
Reporting to Canadians
The results of the consultation will be made available on this website.
If you have any questions, contact us at the Prescription Drug Status Committee.
Report a problem or mistake on this page
- Date modified: